Bicycle Therapeutics (NASDAQ:BCYC) CEO Kevin Lee Sells 10,325 Shares of Stock

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) CEO Kevin Lee sold 10,325 shares of Bicycle Therapeutics stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $6.80, for a total transaction of $70,210.00. Following the sale, the chief executive officer directly owned 629,985 shares of the company’s stock, valued at $4,283,898. This trade represents a 1.61% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Kevin Lee also recently made the following trade(s):

• On Monday, January 5th, Kevin Lee sold 10,989 shares of Bicycle Therapeutics stock. The stock was sold at an average price of $6.46, for a total transaction of $70,988.94.

Bicycle Therapeutics Trading Down 0.6%

Shares of NASDAQ:BCYC opened at $6.57 on Wednesday. The firm has a market cap of $455.76 million, a price-to-earnings ratio of -1.81 and a beta of 1.52. Bicycle Therapeutics PLC Sponsored ADR has a 1 year low of $6.03 and a 1 year high of $15.47. The business has a fifty day simple moving average of $6.97 and a 200 day simple moving average of $7.42.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its earnings results on Thursday, October 30th. The company reported ($0.85) earnings per share for the quarter, topping the consensus estimate of ($1.09) by $0.24. Bicycle Therapeutics had a negative return on equity of 36.05% and a negative net margin of 884.51%.The company had revenue of $11.73 million for the quarter, compared to analyst estimates of $8.25 million. On average, sell-side analysts forecast that Bicycle Therapeutics PLC Sponsored ADR will post -3.06 EPS for the current year.

Analyst Ratings Changes

A number of analysts have issued reports on BCYC shares. JMP Securities set a $12.00 target price on shares of Bicycle Therapeutics in a research note on Friday, October 31st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bicycle Therapeutics in a research note on Monday, December 22nd. Truist Financial began coverage on shares of Bicycle Therapeutics in a research report on Monday, November 24th. They set a “hold” rating and a $10.00 target price on the stock. Royal Bank Of Canada restated a “sector perform” rating and set a $11.00 target price (down from $27.00) on shares of Bicycle Therapeutics in a report on Friday, October 31st. Finally, Citizens Jmp upped their price target on Bicycle Therapeutics from $10.00 to $12.00 and gave the stock a “market outperform” rating in a research note on Friday, October 31st. Seven research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $19.73.

Key Stories Impacting Bicycle Therapeutics

Here are the key news stories impacting Bicycle Therapeutics this week:

• Negative Sentiment: CEO Kevin Lee sold a total of 21,314 shares across trades on Jan. 2 and Jan. 5 (average prices ~$6.80 and ~$6.46), reducing his stake by roughly 1.6–1.7%; he still holds ~619k shares. SEC Form 4 — Kevin Lee
• Negative Sentiment: CFO Alethia Young sold 7,623 shares across Jan. 2 and Jan. 5 trades (avg prices ~$6.80 and ~$6.49), cutting her position by ~3.5–4.7%; she retains ~87k shares. SEC Form 4 — Alethia Young
• Negative Sentiment: COO Alistair Milnes sold 6,660 shares across the two dates (avg prices ~$6.80 and ~$6.46), a ~2.3–2.4% reduction; he still holds ~137k–140k shares. SEC Form 4 — Alistair Milnes
• Negative Sentiment: CAO Travis Alvin Thompson sold 2,432 shares across Jan. 2 and Jan. 5 (avg prices ~$6.80 and ~$6.45), trimming his stake by ~1.6–1.9%; he remains a meaningful holder. SEC Form 4 — Travis Alvin Thompson

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Assetmark Inc. boosted its holdings in Bicycle Therapeutics by 74.9% during the third quarter. Assetmark Inc. now owns 3,625 shares of the company’s stock valued at $28,000 after acquiring an additional 1,552 shares during the period. Ausdal Financial Partners Inc. bought a new position in shares of Bicycle Therapeutics in the second quarter worth about $70,000. Sei Investments Co. acquired a new position in shares of Bicycle Therapeutics during the 2nd quarter worth about $74,000. Virtus Investment Advisers LLC lifted its position in shares of Bicycle Therapeutics by 32.6% during the 2nd quarter. Virtus Investment Advisers LLC now owns 10,821 shares of the company’s stock worth $75,000 after purchasing an additional 2,659 shares during the last quarter. Finally, Ameriprise Financial Inc. bought a new stake in Bicycle Therapeutics during the 2nd quarter valued at approximately $86,000. Institutional investors and hedge funds own 86.15% of the company’s stock.

About Bicycle Therapeutics

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.